# A Direct Head-to-head Comparison of Ustekinumab with Infliximab for the Treatment of Ulcerative Colitis

> **NCT06786507** · — · NOT_YET_RECRUITING · sponsor: **Helwan University** · enrollment: 100 (estimated)

## Conditions studied

- Ulcerative Colitis (UC)

## Interventions

- **DRUG:** Ustekinumab 90 mg
- **DRUG:** Infliximab

## Key facts

- **NCT ID:** NCT06786507
- **Lead sponsor:** Helwan University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-15
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06786507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06786507, "A Direct Head-to-head Comparison of Ustekinumab with Infliximab for the Treatment of Ulcerative Colitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06786507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*